Sanofi SA ((SNY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi SA is conducting a clinical study titled ‘A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa.’ The study aims to evaluate the efficacy and safety of Brivekimig, a drug intended to treat moderate to severe hidradenitis suppurativa, a chronic skin condition.
The intervention being tested is Brivekimig, administered as a subcutaneous injection. The study involves three different dose regimens of Brivekimig and a placebo group to compare outcomes.
This Phase 2b study is designed as a randomized, double-blind, placebo-controlled trial with a parallel group model. It involves quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all unaware of the treatment assignments. The primary purpose of the study is treatment-focused.
The study is not yet recruiting, with the initial submission date recorded as September 5, 2025. The study’s primary completion and estimated completion dates have not been disclosed yet, but the last update was also submitted on September 5, 2025.
The update on this study could influence Sanofi’s stock performance, as positive results may enhance investor confidence and market position, especially in the competitive pharmaceutical industry focusing on dermatological treatments.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.